Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.

And the company might one day follow Galapagos into decentralised manufacturing.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.